X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3017) 3017
Book Review (472) 472
Publication (293) 293
Book Chapter (7) 7
Conference Proceeding (3) 3
Book / eBook (1) 1
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2861) 2861
humans (2161) 2161
animals (1388) 1388
male (1319) 1319
imatinib mesylate (960) 960
female (933) 933
benzamides - pharmacokinetics (932) 932
benzamides (903) 903
benzamides - pharmacology (861) 861
pharmacology & pharmacy (844) 844
oncology (657) 657
adult (651) 651
mice (591) 591
middle aged (571) 571
rats (556) 556
pyrimidines - therapeutic use (493) 493
piperazines - therapeutic use (490) 490
benzamides - therapeutic use (456) 456
antineoplastic agents - therapeutic use (425) 425
aged (415) 415
pharmacokinetics (407) 407
imatinib (399) 399
dose-response relationship, drug (396) 396
benzamides - administration & dosage (387) 387
benzamides - chemistry (366) 366
cancer (361) 361
chronic myeloid-leukemia (355) 355
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (349) 349
pyrimidines - pharmacokinetics (320) 320
piperazines - pharmacokinetics (312) 312
piperazines - pharmacology (307) 307
pyrimidines - pharmacology (297) 297
antineoplastic agents - pharmacology (288) 288
treatment outcome (286) 286
antineoplastic agents - pharmacokinetics (282) 282
chemistry, medicinal (282) 282
administration, oral (280) 280
chronic myelogenous leukemia (277) 277
hematology (270) 270
cell line, tumor (251) 251
pyrimidines - administration & dosage (246) 246
benzamides - adverse effects (245) 245
piperazines - administration & dosage (236) 236
neurosciences (235) 235
analysis (232) 232
structure-activity relationship (226) 226
rats, sprague-dawley (220) 220
research (215) 215
benzamides - chemical synthesis (198) 198
medicine & public health (198) 198
drug therapy (196) 196
benzamides - blood (191) 191
tissue distribution (190) 190
protein-tyrosine kinases - antagonists & inhibitors (185) 185
protein kinase inhibitors - therapeutic use (184) 184
young adult (182) 182
antineoplastic agents - administration & dosage (180) 180
pyrimidines - adverse effects (179) 179
tyrosine kinase inhibitor (179) 179
antineoplastic agents (177) 177
brain - metabolism (177) 177
chronic myeloid leukemia (175) 175
in-vitro (175) 175
mesylate (173) 173
care and treatment (171) 171
benzamides - metabolism (167) 167
aged, 80 and over (165) 165
piperazines - adverse effects (165) 165
antineoplastic agents - adverse effects (164) 164
antimitotic agents (163) 163
biochemistry & molecular biology (162) 162
resistance (162) 162
abridged index medicus (159) 159
expression (158) 158
leukemia (158) 158
time factors (158) 158
adolescent (155) 155
drug resistance, neoplasm (154) 154
tumors (154) 154
article (153) 153
protein kinase inhibitors - pharmacology (153) 153
drug interactions (152) 152
pharmacology/toxicology (150) 150
pharmacology (147) 147
therapy (147) 147
bcr-abl (146) 146
disease models, animal (145) 145
pyrrolidines - pharmacokinetics (145) 145
receptors, dopamine d2 - metabolism (143) 143
cell proliferation - drug effects (140) 140
neoplasms - drug therapy (138) 138
chemistry, organic (135) 135
gastrointestinal stromal tumors - drug therapy (134) 134
health aspects (132) 132
brain - diagnostic imaging (131) 131
apoptosis (130) 130
enzyme inhibitors - pharmacology (130) 130
mutation (130) 130
gastrointestinal stromal tumors (129) 129
cells (127) 127
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2966) 2966
French (13) 13
German (11) 11
Chinese (9) 9
Spanish (9) 9
Japanese (8) 8
Russian (8) 8
Danish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Psychiatry, ISSN 0002-953X, 08/2008, Volume 165, Issue 8, pp. 988 - 995
Journal Article
Journal Article
Analytical and Bioanalytical Chemistry, ISSN 1618-2642, 4/2018, Volume 410, Issue 11, pp. 2815 - 2828
Generation of skin distribution profiles and reliable determination of drug molecule concentration in the target region are crucial during the development... 
Biochemistry, general | Skin penetration | Food Science | Quantification | Drug distribution | Mass spectrometry imaging | Human skin | Laboratory Medicine | MALDI-MSI | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | HUMAN STRATUM-CORNEUM | BIOCHEMICAL RESEARCH METHODS | PENETRATION | MOLECULAR-SIZE | MICROSCOPY | MASS-SPECTROMETRY | TISSUE-SECTIONS | ATOPIC-DERMATITIS | PERCUTANEOUS-ABSORPTION | PSORIASIS | Pyrroles - pharmacokinetics | Benzamides - pharmacokinetics | Skin - metabolism | Humans | Aminopyridines - pharmacokinetics | Pyridines - pharmacokinetics | Drug Discovery - methods | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Pyrroles - administration & dosage | Piperidines - pharmacokinetics | Pyrazoles - pharmacokinetics | Cyclopropanes - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Piperidines - administration & dosage | Pyridines - administration & dosage | Acetamides - pharmacokinetics | Phosphodiesterase 4 Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Skin Absorption | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Pyrimidines - pharmacokinetics | Administration, Topical | Acetamides - administration & dosage | Pharmaceutical research | Topical medication | Pharmaceutical industry | Innovations | Testing | Formulations | Explants | Psoriasis | Medical treatment | Spatial discrimination | Imaging techniques | Ions | Mass spectroscopy | Desorption | Drug development | Tissues | Dermatitis | Ionization | Lasers | Atopic dermatitis | Imaging | Skin diseases | Skin | Mass spectrometry | Spatial resolution | Physicochemical properties | Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2016, Volume 77, Issue 5, pp. 997 - 1003
VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1... 
Defactinib | Medicine & Public Health | Oncology | Cancer Research | Proline-rich tyrosine kinase-2 | VS-6063 | Focal adhesion kinase | Pharmacology/Toxicology | First-in-Asian phase 1 study | NF2/MERLIN | ONCOLOGY | PHARMACOLOGY & PHARMACY | Area Under Curve | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Half-Life | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Focal Adhesion Kinase 2 - antagonists & inhibitors | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Benzamides - therapeutic use | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Drug Administration Schedule | Administration, Oral | Neoplasms - enzymology | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Asian Continental Ancestry Group | Neoplasms - urine | Sulfonamides - therapeutic use | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Sulfonamides - adverse effects | Aged | Focal Adhesion Kinase 1 - antagonists & inhibitors | Sulfonamides - administration & dosage | Tyrosine | Safety and security measures | Colorectal cancer | Clinical trials | Proline | Development and progression | Tumors | Index Medicus | Original
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 10/2012, Volume 37, Issue 11, pp. 2355 - 2367
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2008, Volume 14, Issue 21, pp. 7102 - 7109
Journal Article
Therapeutic Drug Monitoring, ISSN 0163-4356, 2014, Volume 36, Issue 3, pp. 326 - 334
BACKGROUND: The objectives of this study were to evaluate the plasma concentrations of the tyrosine kinase inhibitors (TKIs), imatinib, erlotinib, and... 
Therapeutic drug monitoring | tyrosine kinase inhibitors | unselected patient cohort | trough plasma levels | RESISTANCE PROTEIN | TANDEM MASS-SPECTROMETRY | ANTITUMOR-ACTIVITY | SU11248 | CHRONIC MYELOID-LEUKEMIA | BREAST-CANCER | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | GROWTH-FACTOR | MEDICAL LABORATORY TECHNOLOGY | GASTROINTESTINAL STROMAL TUMORS | PHASE-I | therapeutic drug monitoring | Erlotinib Hydrochloride | Proton Pump Inhibitors - pharmacology | Body Weight | Pyrroles - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Gastric Acid - chemistry | Benzamides - pharmacokinetics | Humans | Middle Aged | Half-Life | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | Drug Monitoring - methods | Dose-Response Relationship, Drug | Tandem Mass Spectrometry | Benzamides - therapeutic use | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Pyrroles - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Piperazines - therapeutic use | Histamine H2 Antagonists | Imatinib Mesylate | Neoplasms - drug therapy | Outpatients | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Plasma | Pharmacology | Kinases | Outpatient care facilities | Cancer | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 01/2014, Volume 24, Issue 1, pp. 52 - 61
OBJECTIVEThe tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia are substrates for the efflux transport protein ATP-binding... 
CGP74588 | Imatinib | Pharmacogenetics | Tyrosine kinase inhibitor | Single-nucleotide polymorphism | Chronic myeloid leukemia | N-desmethyl imatinib | ABCG2 | LOCALIZATION | STEM-CELLS | PROTEIN | STANDARD-DOSE IMATINIB | imatinib | TRANSPORTER ABCG2 | P-GLYCOPROTEIN | RESPONSES | PHARMACOKINETICS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | RESISTANCE | chronic myeloid leukemia | PHARMACOLOGY & PHARMACY | PATIENTS RECEIVING IMATINIB | tyrosine kinase inhibitor | single-nucleotide polymorphism | pharmacogenetics | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Nitriles - pharmacology | Benzamides - pharmacokinetics | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Neoplasm Proteins - metabolism | Nitriles - pharmacokinetics | Quinolines - pharmacology | Thiazoles - pharmacokinetics | Genetic Variation | Quinolines - pharmacokinetics | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette Transporters - metabolism | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Membrane - metabolism | Piperazines - pharmacokinetics | Neoplasm Proteins - genetics | Protein Kinase Inhibitors - pharmacokinetics | Cell Line | Dasatinib | Aniline Compounds - pharmacology | Transduction, Genetic | Genotype | Aniline Compounds - pharmacokinetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | K562 Cells | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Mutation | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN | ABCG2; CGP74588; chronic myeloid leukemia; imatinib; N-desmethyl imatinib; pharmacogenetics; single-nucleotide polymorphism; tyrosine kinase inhibitor
Journal Article
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0306-5251, 07/2006, Volume 62, Issue 1, pp. 97 - 112
Journal Article